Primary pathologies including amyloid-β (Aβ) plaques and neurofibrillary tangles (NFT) develop many years before the onset of dementia symptoms in Alzheimer's disease (AD). Age-related small vessel disease (SVD) is common in elderly subjects and may contribute to the clinical syndrome of AD. Each type of pathology shows a specific spatio-temporal sequence of spreading in the brain.
INTRODUCTION
The biomarker aided diagnosis of Alzheimer's disease (AD) is the new diagnostic paradigm which is reflected in recent proposals to define the pre-dementia phase of AD [1] . According to National Institute on Aging and Alzheimer's Association (NIA-AA) criteria, preclinical AD is defined as the presence of abnormal biomarker levels of Aβ (i.e. reduced levels of cerebrospinal fluid (CSF) or increased amyloid PET binding) in the absence of cognitive impairment [1] . More advanced stages of the preclinical phase of AD include the presence of neurodegeneration as measured by biomarkers (e.g hippocampus atrophy, temporo-parietal FDG-PET hypometabolism or reduced CSF tau levels) and slight cognitive decline [1] . For the diagnosis of mild cognitive impairment (MCI) of the AD type (also called prodromal phase of AD), the presence of amnestic MCI plus abnormal biomarker levels is necessary [2] . Since it cannot be excluded that non-demented individuals diagnosed as preclinical AD according to current research diagnostic criteria [1] do not progress to the dementia stage, some authors prefer the term asymptomatic AD instead of preclinical AD. In the light of current recommendations we use the term preclinical AD to describe all non-demented cases with AD pathology regardless whether they will progress to the symptomatic stages or not.
Apart from primary pathologies of AD including Aβ plaques and neurofibrillary tangles (NFTs), small vessel disease (SVD) is considered an additional pathology that may contribute to cognitive worsening in aging and AD. Although no quantitative consensus diagnostic criteria for SVD exist, the defining MRI-detectable features of SVD include small subcortical infarcts, lacunes, white matter hyperintensities (WMH), enlarged perivascular spaces, and cerebral microbleeds [4] .
Neuropathological studies showed that SVD is present in the majority of elderly subjects and the occurrence of high Aβ pathology coincides with vascular co-pathology in a substantial portion of elderly subjects [5] . Consistent with these post-mortem findings are results from neuroimaging studies, showing that white matter hyperintensities are present in up to 80% of subjects diagnosed with AD dementia [6] . Although it is not clear whether Aβ or tau are associated with the occurrence of SVD, age-related SVD may exacerbate neurodegeneration in AD and thus accelerate clinical 3 progression [3] .
A major question concerns the association between the severity of these pathologies and the manifestation of cognitive deficits and clinical impairment. In order to address this question, we will review first the neuropathological staging models of Aβ plaques, NFTs, and SVD within the preclinical and prodromal phase of AD. Secondly, we will review findings on the spreading of each type of pathology at the level of neuroimaging including PET and MRI findings with regard to 1) confirmation of the neuropathological spatio-temporal staging models for Aβ-plaque and NFT pathologies and 2) as a predictor of cognitive and clinical worsening in the pre-dementia phase of AD.
NEUROPATHOLOGY OF SYMPTOMATIC AND PRECLINICAL AD

Neuropathological hallmarks of AD
Alzheimer's disease is neuropathologically characterized by the presence of amyloid plaques and NFT [7] . Both pathological features are also frequently seen in non-demented individuals [8] . The presence of Aβ plaques is considered to represent AD pathology as recommended by the NIA-AA regardless of the presence of clinical signs of dementia [3] . Accordingly, all non-demented cases with Aβ plaque pathology should be considered as pathologically diagnosed preclinical AD cases (p-preAD) [10] . Whether Aβ plaques in other disorders such as Lewy body disease or traumatic brain injury respresent AD-related copathology or are part of the primary disease is not yet clear and requires further clarification.
Amyloid plaques consist of Aβ aggregates [12] . Modified forms of Aβ, such as pyroglutamate modified AβN3pE and phosphorylated Aβ (pAβ), were detected in a hierarchical sequence throughout the development of AD. [12] The presence of pAβ in Aβ aggregates was, thereby, associated with clinical symptoms of dementia whereas most non-demented cases with Aβ plaques did not show detectable amounts of pAβ [10] (Tab. 1). Neuritic plaques are a subset of Aβ plaques that exhibit dystrophic neurites. Although a development from diffuse, non-neuritic plaques to neuritic plaques has been suggested and may be true for some plaques [15, 18] there are diffuse plaques that never transform into neuritic plaques, e.g. lake-like amyloid in the subicular region [18, 19] .Aβ plaques expand from its initial site of occurrence, the neocortex, into further brain regions in a hierarchical sequence that is described by five phases (Tab. 2a). In different regions of the brain morphologically different types of plaques occur that all contribute to this five-phase sequence of Aβ plaque regional expansion throughout the brain [16, 20] .
NFTs are intracellular aggregates of abnormal phosphorylated τ-protein that form cytoplasmic fibrils [21, 22] . The first sign of τ-pathology in a neuron is the presence of abnormal phosphorylated τ-protein in the axon, soma and the dendrites. The neurons at this stage still look morphologically normal [21] . The next step is the detection of fibrillar τ-containing material in the cytoplasm that grows and step by step occupies more and more parts of the cell soma until the nucleus is displaced and the cell dies. After neuron death the NFT remains as extracellular "ghost-tangle" [21, 24] (Tab. 1). In addition to NFTs τ-aggregates also occur as neuropil threads within dendrites [25] and as dystrophic neurites in neuritic plaques [26] .
NFT pathology consisting of silver-stainable fibrillar τ-aggregates starts in pyramidal neurons of the transentorhinal region (Brodmann area 35) [27] . Interestingly, subcortical nuclei such as the locus coeruleus and the raphe nuclei develop somatic abnormal phosphorylated τ-protein long before the first fibrillar tangles occur in the transentorhinal region [28] . After occurrence of NFTs in the pyramidal neurons of the transentorhinal region in Braak-NFT-stage I NFTs expand into further brain regions in a hierarchical sequence (table 2b) [27] . The distribution of abnormal phosphorylated τ-protein precedes that of fibrillar NFTs [21, 24] and shows a similar distribution Clinical symptoms of AD are found in patients showing advanced stages and phases of NFTpathology and Aβ plaque pathology (Fig. 1A) [20] . Non-demented elderly individuals often showed initial stages and phases of NFT and Aβ plaque pathology (Fig. 1A) [9, 20] . This group of p-preAD cases includes those preAD cases that also exhibit AD biomarkers as recommended for the clinical diagnosis of preAD but may also include cases that do not exhibit a pathological biomarker profile.
Therefore, we use the term p-preAD cases to clarify that p-preAD cases may not be fully identical with clinically diagnosed preAD cases.
VASCULAR PATHOLOGY
Atherosclerosis
Atherosclerosis (AS) is frequent in the elderly and affects large to medium-sized arteries of the entire cardiovascular system (large-vessel disease). AS is characterized by intima proliferation with subsequent accumulation of blood derived lipids and proteins (e.g., cholesterol) in the vessel wall.
This may lead to the development of atherosclerotic plaques, which may calcify, and to fibrosis of the vessel wall. In the brain it mainly affects arteries of the circle of Willis and the carotid arteries, in particular at the level of the carotic bifurcation. AS may cause narrowing of the arteries' lumina, thereby reducing the blood blow for the supported region, while rupture of atherosclerotic plaques often leads to thrombosis that results in either occlusion of the vessel or thromboemboli (for review see: [35] ). AS in the circle of Willis has been linked to AD [37] while others, however, saw no direct association between AS and AD pathology [39] . Zheng and colleagues recently found AS to be associated with microinfarcts and cystic infarcts while no association with AD pathology was seen [40] . However AS of the intracranial vessels is an independent and important risk factor for dementia due to stroke and other potentially reversible pathologies unrelated to AD [41]. Recent findings from the Oxford Project to Investigate Memory and Ageing (OPTIMA) suggest that SVD does not promote AD pathology [47] . In our own cohort of cases the stage of SVD distribution [42] did not differ between p-preAD and AD patients (Fig. 1B) . Taken 
Small vessel disease
SPATIO-TEMPORAL DYNAMICS OF IMAGING MARKER FOR Aβ, TAU AND SMALL VESSEL DISEASE
Spatial patterns of Amyloid PET uptake in AD
Global amyloid PET uptake is abnormally increased in an age-dependent manner in elderly cognitively healthy (HC) subjects, ranging from 18% in HC subjects 60-69 years old to over 65% in subjects > 80 years [49] . In amnestic MCI, the majority of subjects show abnormally increased global amyloid PET uptake [50] . Regional differences in the cerebral distribution of abnormally increased amyloid PET signals have been reported in presymptomatic subjects with autosomaldominantly inherited AD [51] . Amyloid PET revealed lower signals in the hippocampus compared to neocortical brain areas including the prefrontal cortex and the posterior cingulate/precuneus [99] , suggesting that the spreading of Aβ is more prominent in neocortical (SUVR > 1.4) than allocortical brain regions (e.g. hippocampus: SUVR 1.2-1.4) as predicted by post-mortem pathological findings [52] , [53] . Staging of amyloid PET uptake within subcortical structures may be complicated by the fact that amyloid PET images are usually intensity normalized to the pons or cerebellum, i.e. brain regions predicted to be affected in the last phase of Aβ deposition [52] . In addition, amyloid PET tracers may bind to fibrillar rather than to early stage diffuse Aβ plaques.
[101]The PET tracers PIB and flutemetamol are highly associated with ß-sheet (fibrillar) Aβ (PIB tracer) but not with diffuse plaques (PIB and flutemetamol tracers) [53] . The initial pathological stages of Aβ are presumably dominated by the deposition of diffuse plaques [15, 52] , rendering it thus likely that 8 amyloid PET selectively detects only later stages of amyloid PET. These observations are a possible explanation for the bimodal frequency distribution of global amyloid PET uptake [50, 54] 
Amyloid PET as a predictor of clinical progression to AD dementia
Increased global AV45-PET uptake is associated with faster rates of cognitive decline in nondemented subjects [56] . In a pooled analysis of 5 studies, the conversion rate from MCI to AD dementia over 1 -3 years of clinical follow up was 53% in subjects with increased global PIB-PET bindings compared to 7% in MCI subjects with normal PIB-PET uptake [50] . [1] Among elderly HC subjects, 16% of subjects with abnormally high PIB-PET developed MCI or AD dementia after 20 months and 25% after 3 years of follow up, but only 1 out of 73 subjects (1.4%) with low global PIB uptake developed MCI [57] . Similarly, abnormal levels of Aβ (as measured in CSF) were associated with significantly increased risk to progress from HC status to the symptomatic stage T808 [63] , and the 11 C labeled tracer PBB3 [64] . For detecting NFT in AD, in vitro studies in AD brain homogenates showed that such tracers (THK5105 or T808) have a high affinity for tau fibrils, which is 25 -27 times higher than that for Aβ fibrils [65] 11 . Okumara et al. reported that in a group 9 of 8 AD dementia patients the [ 18 F] THK-5105 PET tracer showed increased uptake within the orbitofrontal and venterolateral prefrontal cortex, temporal lobe and posterior parietal lobe [66] . The effect sizes of the group differences were highest within the inferior and superior temporal lobes.
Co-assessed PIB-PET showed a different pattern of cortical PET uptake, with a more pronounced uptake being observed within the prefrontal cortex, cingulate gyrus and parietal cortex [66] . These first results -though based on small sample sizes per study -confirmed neuropathological distribution patterns for tau and Aβ pathology exhibiting different distribution patterns in AD.
It should be cautioned that PET shows inherent limitations such as relatively low spatial resolution that renders it difficult to adequately detect NFT within subcortical structures, where according to the neuropathological staging models tau pathology likely occurs first.
A difference between the tau tracers is the sensitivity for labeling different types of tau lesions across the spectrum of tauopathaties. Tau deposits consist of up to 6 isoforms of tau including 3 repeat (3R tau), 4 repeat (4R tau) and mixed 3 and 4 repeat (3/4 R tau) isoforms and show disease specific morphologies [67] . The tracer PBB3 detects however all of these tau lesions [64] . Thus, these tracers possess different clinical applicability, either as a general marker of tauopathies across AD and fronto-temporal lobe degeneration (PBB3) or for the differential diagnosis to distinguish between tauopathies (THK523).
MICROVASCULAR MRI CHANGES
SVD-related changes including arteriosclerosis and lipohyalinosis are thought to underlie MRI detectable leucoaraiosis (synonymous with WMH) and lacunar lesions in the white matter as discussed above. Neuropathological studies suggest that SVD spreads in a spatio-temporally specific way [68] . A staging model of SVD proposes that microvascular pathologies emerge first in the basal ganglia and the deep white matter (stage I), subsequently the thalamus and cortical brain areas (stage II), and finally the brain stem (stage III) [42] .
In MRI based studies in subjects with genetically caused small vessel disease (CADASIL), the first brain areas affected by vascular changes include the periventricular brain areas (WMH) and basal ganglia (lacunes) [69] . Results from a population based study in elderly subjects corroborate that WMH show a similar region-specific distribution depending on the severity of SVD [70] . Thus, these MRI findings are in general agreement with the post-mortem established staging model of SVD.
For the association between WMH and cognitive decline and clinical progression, a meta-analysis showed that in population based studies, WMH were associated with a higher risk of incident amnestic MCI and AD dementia, as well as faster rates of cognitive decline in executive function and memory [75] despite varying reports in the literature [71, 73] . Global WMH volume predicted cognitive decline independently from amyloid pathology, suggesting that SVD contributes to the cognitive decline in AD [76] .
Even though the majority of the studies on WMH, used a lump measure of WMH within the whole brain, results from several studies suggest that the locality of WMH is critical for the clinical picture, with periventricular WMH being stronger associated with executive function compared to WMH in the deep white matter [75] . WMH may exert an effect onto cognitive dysfunction by disrupting fiber tracts and thus exerting locally specific effects onto neural network function [77] . In subjects with MCI, reduced episodic memory and executive function were each associated with a different topology of WMH distribution in patients with MCI [78] . A ROI-analysis of WMH within a priori hypothesized neural networks showed that WMH selectively within fronto-parietal and basal ganglia/cerebellar brain regions were associated with faster decline in executive function in subjects with MCI [79] .
Together these results suggest that 1) WMH contribute to cognitive decline and clinical worsening independently from amyloid pathology and 2) WMH location matters for the prediction of decline in specific cognitive domains in subjects at increased risk of AD. Future studies will need to explore whether neural-network specific measures of WMH are predictive of the clinical progression in the course of AD.
CONCLUSIONS
Amyloid PET likely detects advanced stages of Aβ deposition possibly due to low uptake to diffuse plaques and increased uptake to more mature plaques, the latter of which are more frequent in later stages of Aβ deposition [15, 53] . It can be speculated that these plaque-type specific differences of amyloid PET tracer uptake contribute to the observation that subjects with an abnormal amyloid PET scan show globally increased amyloid PET uptake in the brain. This may limit the spatial information included in amyloid PET with regard to distinguish early vs late stage of Aβ deposition.
The best established evidence for a predictive value is the classification of normal vs abnormal levels of amyloid PET uptake using a binary cut-off point of global amyloid PET uptake for the prediction of clinical progression in AD [50] . The proportion of "false positives" by biomarkerbased classification of preclinical and prodromal AD is not sufficiently established and overdiagnosis of preclinical AD is a potential problem. The use of multiple markers focusing on copathologies such as NFT and SVD may partially alleviate this problem. Current biomarker based concepts of the progression of AD within the preclinical and MCI stage take neither SVD nor spatially specific patterns of the spread of Aβ plaques and NFTs into account. In addition, the occurence of amyloid PET-negative cases [53] fulfilling neuropathological criteria for AD pathology, indicates that current biomarkers do not sensitively detect all early stages of AD pathology. Based on post-mortem neuropathological criteria as the gold standard, at least two groups of p-preAD cases exist: 1. Amyloid PET-positive preAD cases and 2. Amyloid-PET negative, clinically silent p-preAD cases. Thus, two major questions remain to be addressed in future neuroimaging studies: 1) increasing the sensitivity of neuroimaging markers and summary statistics to detect those healthy control cases which show AD-like neuropathology but remain yet normal with regard to global amyloid PET and/or tau PET binding, and 2) assessing the clinically predictive value of neuroimaging markers of primary pathology in cognitive normal subjects in order to address the problem of over-diagnosing.
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Supplementary Material
Cerebral amyloid angiopathy CAA is caused by focal to widespread deposition of Aβ within leptomeningeal and intracortical arteries, arterioles, capillaries, and rarely veins. The predominating Aβ species in CAA is Aβ-40 and the Aβ-40/Aβ-42 ratio is higher than in Aβ plaques [1] [2] [3] . CAA may cause fibrinoid necrosis, intimal thickening and microaneurysms. Of note, two types of CAA can be distinguished; i) CAA type 1 refers to Aβ deposits in the capillary wall and Aβ depositions in arteries and veins may be present in addition, while ii) no capillary Aβ is seen in CAA type 2 where Aβ deposits are only seen in arterial vessels [4] . Pericapillary Aβ on the other hand refers to Aβ deposits in the glia limitans and adjacent neuropil [5] .
Sporadic, non-familial CAA is present in 82-98% of AD patients, but is also frequently observed in brains of elderly non-demented individuals with a prevalence of almost 100% in the oldest old [6, 7] . The stage of CAA distribution throughout the brain [8] was increased in AD cases compared to p-preAD cases (Fig. 1B) . In AD, CAA is often associated with ApoE2 and ApoE4 alleles [9] . The occipital lobe has been reported to be the site most frequently and severely affected by CAA, followed by either frontal, temporal or parietal lobes (see [7, 10] ).
CAA may cause lobar intracerebral hemorrhages (ICH) and microbleeds [11] and is considered a risk factor for non-traumatic ICHs in the elderly where it is present in up to 20% of all cases with ICH [12] . However, in a large autopsy cohort the majority of cases with CAA related ICH had hypertension during life and the prevalence of ICH was similar in cases with and without CAA (around 5%) [13, 14] suggesting that additional factors might play a role and hypertension has been indeed suggested to be an important additional causal factor in patients with CAA-related ICH [15, 16] . On the other hand, CAA associated hemorrhages affect lobar regions, while hypertension alone is typically associated with hemorrhages in the deep gray matter and in surgically resected lobar hematomas CAA is frequently present [17] . While moderate to severe CAA is considered to be an independent risk factor for cognitive impairment [18] its influence on cognitive function is not clear. Studies that have shown a significantly increased prevalence of CAA in demented subjects often did not control for additional pathologies such as neuritic AD pathology [19, 20] . However, an association between severe CAA and dementia is well documented but may be partly attributed to the high co-occurence of CAA and other pathologies such as neuritic plaques [21, 22] . In familial forms of CAA with very severe CAA associations between CAA and dementia independent of concomitant pathology have been reported [23] .
Vascular lesions that are caused by CAA include hemorrhage/microhemorrhage as well as cerebral ischemia and inflammatory changes which could directly contribute to dementia. In demented patients severe CAA has indeed been associated with old microinfarcts [24] . In addition, associations between CAA, white matter changes and cognitive impairment suggest that advanced CAA may cause clinically important vascular dysfunction [25] . CAA may also contribute to cognitive decline by impairing the perivascular drainage pathway [26] leading to increased soluble Aβ in the brain parenchyma, which correlates with cognitive decline [27] .
